CJC-1295 without DAC 10mg + Ipamorelin 10mg
CJC-1295 / Ipamorelin 10mg/10mg Blend – Research Peptide
Product OverviewThis blend combines CJC-1295 (Modified GRF 1-29) and Ipamorelin in a 1:1 ratio, delivering 10mg of each peptide per vial (20mg total). CJC-1295 is a GHRH analog, while Ipamorelin functions as a growth hormone secretagogue. Together, they are used in research to study how complementary pathways within the growth hormone axis interact. The product is supplied as a lyophilized powder blend for laboratory use.
Mechanism of ActionIn preclinical models, this combination activates two distinct pathways involved in growth hormone signaling. CJC-1295 stimulates GHRH receptor activity, while Ipamorelin targets the ghrelin receptor (GHSR-1a). When both are engaged, researchers can evaluate how these mechanisms work together and influence growth hormone release patterns under controlled conditions.
Research BackgroundStudies by Raun et al. have outlined the pharmacological properties of both peptides individually, including receptor specificity and signaling behavior. Additional research, such as Liu et al. (2017), has shown that simultaneous activation of GHRH and ghrelin pathways can enhance growth hormone output in animal models. These findings support the use of this combination for investigating synergistic effects in GH-related research.
Product Specifications & Storage
Form: White lyophilized powder blend
Total quantity: 20mg (10mg CJC-1295 + 10mg Ipamorelin)
Storage: -20°C, sealed, dry, and protected from light
Reconstitution: Sterile saline or bacteriostatic water
Stability: Up to 24 months under proper storage conditions
Purity: >99% (HPLC tested for each peptide)
Format: Single vial
DisclaimerFor research use only. Not intended for human consumption, medical use, or therapeutic application. All information is based on preclinical research. Proper regulatory approval is required for laboratory use.
